source
- Gilead reports positive Phase 3 HIV results while Merck's Trodelvy fails in lung cancer trialGilead Sciences announced that its Phase 3 HIV trial met its primary efficacy endpoint, delivering a positive readout for the experimental therapy. In a separate study, Merck reported that its Pha…
- GSK to acquire cancer drug developer Nuvalent for $10.6 billionGSK announced an agreement to purchase Nuvalent, a company focused on cancer therapies, in a transaction valued at $10.6 billion. The acquisition is intended to broaden GSK’s oncology portfolio an…